In a report released today, Silvan Tuerkcan from JMP Securities reiterated a Buy rating on Relay Therapeutics (RLAY – Research Report), ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...

RLY-2608 + ribociclib + fulvestrant dose escalation is currently testing biologically active doses of RLY-2608 and is on track to identify a dose of RLY-2608 that is combinable with full-dose ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

ribociclib (Kisqali) is also recommended as a Category 1 preferred regimen for first- and subsequent-line therapies in HR+/HER2- MBC in combination with fulvestrant. NCCN makes no warranties of any ...

Palazestrant demonstrates superior anti-tumor efficacy over fulvestrant in combination ... studies with CDK4/6 inhibitors (palbociclib and ribociclib), a PI3Ka inhibitor (alpelisib), and an ...

The study results indicated that OP-3136, when combined with fulvestrant, palazestrant, or CDK4/6 inhibitors, displayed increased inhibition of T47D cells, particularly noting the substantial ...

Kisqali® (ribociclib) is a selective cyclin-dependent ... HER2- advanced or MBC in combination with an AI as initial ET or fulvestrant as initial ET or following disease progression on ET in ...